Research and regulatory
📋 Development stage
Phase III combination trials (CagriSema); NDA filed with FDA, decision expected Q4 2026.
⚖️ Legal and regulatory
Investigational; not yet FDA approved as monotherapy or in combination.
⚠️ Side effects
GI symptoms (nausea, constipation) similar to GLP-1 agonists; injection site reactions